WESPAC Advisors LLC Invests $683,000 in Amgen Inc. $AMGN

WESPAC Advisors LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,087 shares of the medical research company’s stock, valued at approximately $683,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after purchasing an additional 165,281 shares in the last quarter. State Street Corp increased its holdings in shares of Amgen by 0.6% in the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after purchasing an additional 177,035 shares in the last quarter. Capital International Investors increased its holdings in shares of Amgen by 1.5% in the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after purchasing an additional 282,219 shares in the last quarter. Capital World Investors lifted its stake in shares of Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares during the period. Finally, Capital Research Global Investors boosted its holdings in Amgen by 2.7% during the third quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock worth $1,335,168,000 after buying an additional 122,631 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Amgen stock opened at $348.77 on Monday. The company has a market cap of $188.01 billion, a price-to-earnings ratio of 24.51, a price-to-earnings-growth ratio of 3.46 and a beta of 0.45. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The stock’s 50-day moving average is $362.59 and its 200-day moving average is $330.59.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the company earned $5.31 EPS. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s payout ratio is 70.84%.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research analyst reports. Guggenheim increased their target price on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. BMO Capital Markets increased their price objective on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average target price of $354.60.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.